Scientists seek clues to rare cancer syndrome in 5,000-Person study

NCT ID NCT01443468

Recruiting now Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 4 times

Summary

This study aims to learn more about Li-Fraumeni syndrome (LFS), a genetic condition that raises the risk of several cancers. Researchers will study up to 5,000 people with LFS or related cancer histories to find new genes, understand how the TP53 gene works, and identify factors that may increase or lower cancer risk. Participants fill out questionnaires, give blood or cheek cell samples, and may have optional cancer screenings over several years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LI-FRAUMENI SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Li-Fraumeni syndrome Li-fraumeni-like syndrome neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LI-FRAUMENI SYNDROME NEOPLASMS TP53 MUTATIONS

Contacts and locations

Locations

National Cancer Institute - Shady Grove
RECRUITING

Bethesda, Maryland, 20892, United States
National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.